Cargando…

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab

We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg intravenously (days 1, 15) versus placebo, both plus paclitaxel 80 mg/m(2) intravenously (days 1, 8, 15), every 4 weeks in patients with previously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gil-Delgado, Maria Angeles, Lucidarme, Olivier, Bachet, Jean Baptiste, Mahi, Naima, Khayat, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2018
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167727/ https://www.ncbi.nlm.nih.gov/pubmed/30283289 http://dx.doi.org/10.1159/000490906

Ejemplares similares

Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
por: Okamoto, Takeshi, et al.
Publicado: (2022)

The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs
por: Yang, Hongqiong, et al.
Publicado: (2021)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Gastroesophageal junction adenocarcinoma metastasizing to gingiva
por: Masamatti, Smita S, et al.
Publicado: (2013)

Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea
por: Kim, Jin-Jo
Publicado: (2018)

Genetic Polymorphisms at TIMP3 Are Associated with Survival of Adenocarcinoma of the Gastroesophageal Junction
por: Bashash, Morteza, et al.
Publicado: (2013)

The impact of hiatal hernia on survival outcomes in patients with gastroesophageal junction adenocarcinoma
por: Tanaka, Yuya, et al.
Publicado: (2021)

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2016)

Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma
por: Hirata, Yuki, et al.
Publicado: (2023)

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
por: Klempner, Samuel J., et al.
Publicado: (2018)

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)
por: Lorenzen, Sylvie, et al.
Publicado: (2023)

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
por: Han, Hye Sook, et al.
Publicado: (2021)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States †
por: Kim, Bradford J., et al.
Publicado: (2020)

Mediastinal Lymph Node Dissection in Gastroesophageal Junction Adenocarcinoma
por: Kim, Jin-Jo
Publicado: (2023)

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma(†)
por: Al-Batran, S.-E., et al.
Publicado: (2016)

Meningeal Carcinomatosis: A Metastasis from Gastroesophageal Junction Adenocarcinoma
por: Dam, Tanya, et al.
Publicado: (2013)

Incidence of Microscopically Positive Proximal Margins in Adenocarcinoma of the Gastroesophageal Junction
por: Gao, Fei, et al.
Publicado: (2014)

Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction
por: Clemons, Nicholas J, et al.
Publicado: (2013)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
por: Sigrand, Julie, et al.
Publicado: (2016)

Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas
por: Ferrer-Torres, Daysha, et al.
Publicado: (2016)

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
por: Das, Satya, et al.
Publicado: (2018)

ASO Author Reflections: Challenges in the Management of Gastroesophageal Junctional Adenocarcinoma
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Midesophageal Metastatic Disease After Treatment of Gastroesophageal Junction Adenocarcinoma
por: Brotherton, Tim, et al.
Publicado: (2022)

Expression and Prognostic Value of RAD51 in Adenocarcinoma at the Gastroesophageal Junction
por: Redati, Darebai, et al.
Publicado: (2022)

Gastroesophageal junction adenocarcinoma 1-year after sleeve gastrectomy
por: Brown, Kevin C, et al.
Publicado: (2023)

Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
por: Feka, Joy, et al.
Publicado: (2023)

Surgical pathology of adenocarcinomas arising around or within the gastroesophageal junction
por: Dislich, Bastian, et al.
Publicado: (2022)

A Young Adult Patient with Nonalcoholic Steatohepatitis Developed Severe Gastroesophageal Varices Associated with Severe Obesity and Diabetes Mellitus
por: Honma, Yuichi, et al.
Publicado: (2018)

Erythema Gyratum Repens in Long-Term Smoker
por: Sauvageau, Andrew P., et al.
Publicado: (2019)

Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas
por: Gao, Xianchun, et al.
Publicado: (2021)

Barrett's Esophageal Adenocarcinoma Involving a White Globe Appearance within the Long-Segment Barrett's Esophagus
por: Kubota, Yo, et al.
Publicado: (2020)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia
por: Jeromen, Ana, et al.
Publicado: (2012)

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
por: Zhao, Qun, et al.
Publicado: (2015)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction
por: Bornschein, Jan, et al.
Publicado: (2019)

Paraneoplastic Leukemoid Reaction in Gastroesophageal Junction Adenocarcinoma: A Case Report
por: Chang*, Kevin Wei-Lun, et al.
Publicado: (2020)

The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma
por: Dinneen, Kate, et al.
Publicado: (2021)

Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction
por: Li, Shoumiao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mjuvs9bkq4longc4kbnp2uc8bc